Price$0.05-98.01 (-99.95%)
2026-03-052026-06-08
News · 26 weeks35-12%
2025-12-142026-06-07
Mix2790d
- SEC Filings19(70%)
- Insider3(11%)
- Leadership2(7%)
- Other2(7%)
- M&A1(4%)
Latest news
25 items- PRIgnite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy SelectionRegistry expected to pair Ignite's reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite over the course of the agreement Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics") a subsidiary of Aditxt, Inc. (NASDAQ:ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite's CLIA-certified Reverse Phase Protein Array ("RPPA") platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection. The initiative is expected to
- SECAditxt Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to ShareholdersSeasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
- SECAditxt Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form PRE 14A filed by Aditxt Inc.PRE 14A - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 10-Q filed by Aditxt Inc.10-Q - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on May 18, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the annual meeting of stockholders held on May 1, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025869. As a res
- SECAditxt Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aditxt, Inc. (0001726711) (Filer)
- INSIDERLarge owner Hrt Financial Lp sold $9,338 worth of Class A Shares (33,215 units at $0.28), decreasing direct ownership by 27% to 88,377 units (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- SECSEC Form 424B3 filed by Aditxt Inc.424B3 - Aditxt, Inc. (0001726711) (Filer)
- INSIDERLarge owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Hrt Financial Lp claimed ownership of 133,574 units of Class A Shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- SECSEC Form EFFECT filed by Aditxt Inc.EFFECT - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form S-3 filed by Aditxt Inc.S-3 - Aditxt, Inc. (0001726711) (Filer)
- SECAmendment: Aditxt Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form DEF 14A filed by Aditxt Inc.DEF 14A - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Other Events8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 10-K filed by Aditxt Inc.10-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 424B5 filed by Aditxt Inc.424B5 - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form PRE 14A filed by Aditxt Inc.PRE 14A - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerBusch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
ADTX FAQ
6 questionsWhat does Aditxt Inc. do?
ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin...Where does ADTX stock trade?
Aditxt Inc. (ADTX) is listed on NASDAQ.What sector and industry is ADTX in?
Aditxt Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aditxt Inc. go public?
Aditxt Inc. (ADTX) completed its IPO in 2020.What companies are similar to ADTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ADTX side-by-side with any of them on Quantisnow.How can I track ADTX on Quantisnow?
Quantisnow aggregates Aditxt Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADTX to receive live email and push alerts on every new disclosure.